CSIMarket
 

Fibrogen Inc   (FGEN)
Other Ticker:  
 

Fibrogen Inc 's

Competitiveness


 

FGEN Sales vs. its Competitors Q3 2023







Revenue Growth Comparisons




Net Income Comparison




<<  FGEN Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Fibrogen Inc Contracts

'SAN FRANCISCO, May 23, 2024' - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company committed to pioneering therapeutic advancements for serious unmet medical needs, is celebrating a significant milestone with the announcement of positive interim data from the dose escalation portion of the Phase 1b/2 study of FG-3246 (FOR46). This study is conducted by the Universit...

'FibroGen Showcases Clinical Breakthroughs in Cancer Therapy at ASCO 2024 and Upcoming KOL Investor Event''SAN FRANCISCO, May 23, 2024' - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company committed to pioneering therapeutic advancements for serious unmet medical needs, is celebrating a significant milestone with the announcement of positive interim data from the dose escalation portion of the Phase 1b/2 study of FG-3246 (FOR46). This study is conducted by the University of California San Francisco and is designed to evaluate the efficacy of FG-3246, a potential first-in-class anti-CD46 antibody drug conjugate (ADC) containing an MMAE payload, in combination with enzalutamide in patients suff...

Promising Results of FG-3246 in Phase 1 Monotherapy Study for Metastatic Castration-Resistant Prostate Cancer

This article provides an overview of the topline results from the Phase 1 study conducted by FibroGen, Inc. and sponsored by Fortis Therapeutics. The study evaluated the potential of FG-3246, an anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload, as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously progressed on androgen receptor-signaling inhibitors (ARSI).Study Details:The Phase 1 trial was designed as a dose-escalation and dose-expansion study, aiming to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of FG-3246 in mCRPC patients. The trial enrolled participants with progressive tumors despite ...

FibroGen Assumes Full Control of Revolutionary Anemia Drug, Roxadustat, Except in China and South Korea; Retention of China Agreement Highlights Continued Focus on Expanding Reach in Largest CKD Market

FibroGen, a leading biopharmaceutical company, has recently announced that it has regained all rights to its innovative therapeutic drug, Roxadustat, from AstraZeneca, with the exception of China and South Korea. The decision marks a significant development in the partnership between both companies. The FibroGen AstraZeneca China Agreement for Roxadustat will remain intact, underscoring the importance of this medication in the Chinese market. Roxadustat is a revolutionary drug designed to treat anemia caused by chronic kidney disease (CKD) in patients who are both on dialysis and not on dialysis. The medication has shown promising results in clinical trials, demonstrating its ability to raise hemoglobin leve...

FibroGen's Pamrevlumab Shows Promise in Pancreatic Cancer Clinical Program

FibroGen, Inc. (NASDAQ: FGEN) has recently announced its plans to host...





Who are Fibrogen Inc 's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com